GENE GUIDE

PPP2R5D-Related Syndrome

This guide is not meant to take the place of medical advice. Please consult with your doctor about your genetic results and health care choices. This Gene Guide was last updated on 2024. As new information comes to light with new research we will update this page. You may find it helpful to share this guide with friends and family members or doctors and teachers of the person who has PPP2R5D-Related Syndrome.
a doctor sees a patient

PPP2R5D-related syndrome is also called PPP2R5D-related neurodevelopmental disorder or Jordan’s syndrome. For this webpage, we will be using the name PPP2R5D-related syndrome to encompass the wide range of variants observed in the people identified.

PPP2R5D-related syndrome happens when there are changes to the PPP2R5D gene. These changes can keep the gene from working as it should.

Key Role

The PPP2R5D gene plays an important role in the development and function of brain cells.

Symptoms

Because the PPP2R5D gene is important for brain activity, many people who have PPP2R5D-related syndrome have:

  • Autism
  • Intellectual disability
  • Epilepsy
  • Low muscle tone
  • Delayed walking
  • Language impairment
  • Behavioral issues or impulses
  • Low blood pressure
  • Brain changes seen on magnetic resonance imaging (MRI)

PPP2R5D-related syndrome is a genetic condition, which means that it is caused by variants in genes. Our genes contain the instructions, or code, that tell our cells how to grow, develop, and work. Every child gets two copies of the PPP2R5D gene: one copy from their mother’s egg, and one copy from their father’s sperm. In most cases, parents pass on exact copies of the gene to their child. But the process of creating the egg or sperm is not perfect. A change in the genetic code can lead to physical issues, developmental issues, or both.

Sometimes a spontaneous variant happens in the sperm, egg or after fertilization. When a brand new genetic variant happens in the genetic code is called a ‘de novo’ genetic variant. The child is usually the first in the family to have the genetic variant.

De novo variants can take place in any gene. We all have some de novo variants, most of which don’t affect our health. But because PPP2R5D plays a key role in development, de novo variants in this gene can have a meaningful effect.

Research shows that PPP2R5D-related syndrome is often the result of a de novo variant in PPP2R5D. Many parents who have had their genes tested do not have the PPP2R5D genetic variant found in their child who has the syndrome. In some cases, PPP2R5D-related syndrome happens because the genetic variant was passed down from a parent.

Autosomal dominant conditions

PPP2R5D-related syndrome is an autosomal dominant genetic condition. This means that when a person has the one damaging variant in PPP2R5D they will likely have symptoms of PPP2R5D-related syndrome. For someone with an autosomal dominant genetic syndrome, every time they have a child there is a 50 percent chance they pass on the same genetic variant and a 50 percent chance they do not pass on the same genetic variant.

Autosomal Dominant Genetic Syndrome

GENE / gene
GENE / gene
Genetic variant that happens in sperm or egg, or after fertilization
GENE / gene
Child with de novo genetic variant
gene / gene
Non-carrier child
gene / gene
Non-carrier child

Why does my child have a change in the PPP2R5D gene?

No parent causes their child’s PPP2R5D-related syndrome. We know this because no parent has any control over the gene changes that they do or do not pass on to their children. Please keep in mind that nothing a parent does before or during the pregnancy causes this to happen. The gene change takes place on its own and cannot be predicted or stopped.

Each family is different. A geneticist or genetic counselor can give you advice on the chance that this will happen again in your family.

The risk of having another child who has PPP2R5D-related syndrome depends on the genes of both biological parents.

  • If neither biological parent has the same genetic variant found in their child, the chance of having another child who has the syndrome is on average 1 percent. This 1 percent chance is higher than the chance of the general population. The increase in risk is due to the very unlikely chance that more of the mother’s egg cells or the father’s sperm cells carry the same genetic variant.
  • If one biological parent has the same genetic variant found in their child, the chance of having another child who has the syndrome is 50 percent.

For a symptom-free brother or sister of someone who has PPP2R5D-related syndrome, the sibling’s risk of having a child who has PPP2R5D-related syndrome depends on the sibling’s genes and their parents’ genes.

  • If neither parent has the same genetic variant causing PPP2R5D-related syndrome, the symptom-free sibling has a nearly 0 percent chance of having a child who would inherit PPP2R5D-related syndrome.

As of 2024, at least 138 people with PPP2R5D-related syndrome have been identified in a medical clinic and the Simons Searchlight registry.

People who have PPP2R5D-related syndrome may look different. Appearance can vary and can include some but not all of these features:

  • Larger than average head size
  • Widely spaced eyes
  • Large, noticeable forehead
  • Low ear lobes
  • Eye issues
  • Bone and joint issues

Scientists and doctors have only just begun to study PPP2R5D-related syndrome. At this point, there are no medicines designed to treat the syndrome. A genetic diagnosis can help people decide on the best way to track the condition and manage therapies. Doctors can refer people to specialists for:

  • Physical exams and brain studies
  • Genetics consults
  • Development and behavior studies
  • Other issues, as needed

A developmental pediatrician, neurologist, or psychologist can follow progress over time and can help:

  • Suggest the right therapies. This can include physical, occupational, speech, or behavioral therapy.
  • Guide individualized education plans (IEPs).

Specialists advise that therapies for PPP2R5D-related syndrome should begin as early as possible, ideally before a child begins school.

If seizures happen, consult a neurologist. There are many types of seizures, and not all types are easy to spot. To learn more, you can refer to resources such as the Epilepsy Foundation’s website: epilepsy.com/…t-is-epilepsy/seizure-types

This section includes a summary of information from major published articles. It highlights how many people have different symptoms. To learn more about the articles, see the Sources and references section of this guide.

Speech and Learning

About one-half of people with PPP2R5D-related syndrome had developmental delay or intellectual disability. People with PPP2R5D-related syndrome also had a language disorder. Research suggests that people with variants p.Asp251Ala, p.Asp251Tyr, p.Asp251His, p.Asp251Val, and p.Glu200Lys had better expressive language skills, personal care, and social skills compared with people with variants p.Glu198Lys and p.Trp207Arg.

  • 44 out of 104 people had developmental delay or intellectual disability (42 percent)
  • 58 out of 88 people had a language disorder (66 percent)
42%
44 out of 104 people had developmental delay or intellectual disability.
66%
58 out of 88 people had a language disorder.

Behavior

Autism diagnosis occurred in about 1 out of 3 people with PPP2R5D-related syndrome. Increased aggression was reported more often for people with variants p.Glu198Lys and p.Glu200Lys than for people with variants in 251. People with variant p.Glu200Lys reported more oppositional behavior as they got older. People with PPP2R5D-related syndrome had increased attention difficulties and hyperactivity as they got older, except for people with variants in 251.

  • 25 out of 84 people had autism or features of autism (30 percent)

Brain

Almost one-half of people with PPP2R5D-related syndrome had seizures. Seizure types included tonic–clonic (grand mal) seizures and myoclonic seizures. The average age of seizure onset was 2.3 years, but some people developed seizures as early as birth or as late as almost 18 years old. Many people had larger than average head size, also called macrocephaly, and lower than average muscle tone.

  • 42 out of 98 people had seizures (43 percent)
  • 12 out of 33 people had tonic–clonic seizures (36 percent
  • 10 out of 33 people had myoclonic seizures (30 percent)
  • 67 out of 99 people had macrocephaly (68 percent)
  • 77 out of 98 people had lower than average muscle tone (79 percent)
Human head showing brain outline
43%
42 out of 98 people had seizures.
36%
12 out of 33 people had tonic–clonic seizures.
30%
10 out of 33 people had myoclonic seizures.
68%
67 out of 99 people had macrocephaly.
79%
77 out of 98 people had lower than average muscle tone.

Feeding and digestion

People with PPP2R5D-related syndrome had diarrhea or gastroesophageal reflux disease (GERD).

  • 17 out of 72 people had diarrhea (24 percent)
  • 20 out of 72 people had GERD (28 percent)

Vision

Some people had vision issues, including strabismus (crossed eyes) and astigmatism (an imperfection of the eye that causes blurred distance and near vision).

  • 20 out of 72 people had strabismus (28 percent)
  • 12 out of 72 people had astigmatism (17 percent)

Other findings

There have been seven people with PPP2R5D-related syndrome that developed early onset parkinsonism. Ages of diagnosis were within the range of 25 to 42 years old.

About 2 out of 3 children with a pathogenic PPP2R5D variant had excessive drooling.

Where can I find support and resources?

PPP2R5D Foundation Website

Jordan’s Guardian Angels’ mission is to conduct research seeking answers to rare genetic mutations affecting children and adults, and assist and improve the quality of life for children and families.

Simons Searchlight

Simons Searchlight is an online international research program, building an ever growing natural history database, biorepository, and resource network of over 175 rare genetic neurodevelopmental disorders. By joining their community and sharing your experiences, you contribute to a growing database used by scientists worldwide to advance the understanding of your genetic condition. Through online surveys and optional blood sample collection, they gather valuable information to improve lives and drive scientific progress. Families like yours are the key to making meaningful progress. To register for Simons Searchlight, go to the Simons Searchlight website at www.simonssearchlight.org and click “Join Us.”

Sources and References

The content in this guide comes from published studies about PPP2R5D-related syndrome. Below you can find details about each study, as well as links to summaries or, in some cases, the full article. A PubMed search for PPP2R5D articles can be found here. You can also visit the Simons Foundation’s SFARI Gene website to see information for researchers about this gene.

  • Madaan, P., Kaur, A., Saini, L., Paria, P., Vyas, S., Sharma, A. R., & Sahu, J. K. (2022). PPP2R5D-related neurodevelopmental disorder or developmental and epileptic encephalopathy?: A novel phenotypic description and review of published cases. Neuropediatrics, 53(1), 20-25. https://pubmed.ncbi.nlm.nih.gov/34448180/
  • Mahale, R., Arunachal, G., Chadha, D., Padmanabha, H., M, P., & Pavagada, M. (2024). Early-onset levodopa responsive parkinsonism in PPP2R5D mutation. Parkinsonism & Related Disorders, 123, 106952. https://pubmed.ncbi.nlm.nih.gov/38582018/
  • Ming, N. R., Noble, D., Chussid, S., Ziegler, A., & Chung, W. K. (2024). Caregiver-reported dental manifestations in individuals with genetic neurodevelopmental disorders. International Journal of Paediatric Dentistry, 34(2), 145-152. https://pubmed.ncbi.nlm.nih.gov/37655712/
  • Oyama, N., Vaneynde, P., Reynhout, S., Pao, E. M., Timms, A., Fan, X., Foss, K., Derua, R., Janssens, V., … & Mirzaa, G. M. (2023). Clinical, neuroimaging and molecular characteristics of PPP2R5D-related neurodevelopmental disorders: An expanded series with functional characterisation and genotype-phenotype analysis. Journal of Medical Genetics, 60(5), 511-522. https://pubmed.ncbi.nlm.nih.gov/37655712/
  • Yau, W. Y., Vijayan, S., & Ravenscroft, G. (2024). PPP2R5D heterozygous pathogenic variant causes early-onset parkinsonism and treatment implications: A case report. Parkinsonism & Related Disorders, 124, 106976. https://pubmed.ncbi.nlm.nih.gov/38718479/